Precision Nutrition: What Lipids, CGMs, and Genes Can Prove

Precision nutrition can measure differences between people with impressive detail. It has not yet shown that those measurements consistently produce better health outcomes than well-delivered standard dietary advice.

Three approaches make that gap unusually clear. A plasma lipidome score tracks the metabolic changes that follow replacing saturated fat with unsaturated fat and predicts future cardiometabolic risk. Algorithms that predict post-meal glucose responses can rank foods differently for different people, yet the largest available randomized trial found no advantage over standard counseling. A common FADS1 variant changes blood fatty-acid composition after dietary fat exposure, but it has not identified people who gain more diabetes protection from nuts or plant oils.

The biology is individual. The prescription still needs proof.

A lipidome score has the strongest case—so far

The best evidence comes from Eichelmann et al.'s 2024 Nature Medicine study. Its starting point was the DIVAS randomized controlled trial: over 16 weeks, 195 participants ate either a saturated-fat-rich control diet (n=65) or one of two diets richer in unsaturated fats (n=130). The intervention replaced 8% of total energy from saturated fatty acids with unsaturated fatty acids. Because the two unsaturated-fat diets produced similar lipidome shifts, researchers pooled them for this analysis.

Lipidomics data were available for 113 participants. Of 111 measured fatty-acid concentrations across lipid classes, 45 differed after the dietary intervention at a false-discovery-rate threshold below 0.05. The researchers combined those changes into a weighted Multilipid Score, or MLS.

That score did more than mirror LDL cholesterol or triglycerides. In the prospective EPIC-Potsdam cohort of roughly 27,000 people, a higher MLS was associated with 32% lower cardiovascular disease risk and 26% lower type 2 diabetes risk after adjustment for body mass index, LDL cholesterol, blood pressure, smoking, and other conventional factors. The score also added predictive information beyond LDL cholesterol and triglycerides.

Those are associations, not proof that raising an MLS prevents disease. Still, the investigators tested a lower-resolution version, the reduced MLS or rMLS, in the Nurses' Health Study cohorts and examined it again in PREDIMED. In PREDIMED, participants who began with an unfavorable rMLS appeared to receive more type 2 diabetes risk reduction from the Mediterranean diet intervention. That is a genuine precision-nutrition signal: baseline biology may help identify who benefits most.

The practical implication does not require a mass spectrometer. Replacing some saturated fat with unsaturated fat from foods such as nuts, seeds, fish, olive oil, and other plant oils already fits mainstream cardiometabolic advice. The MLS makes that familiar recommendation biologically more detailed; it does not yet turn it into a clinic-ready personalized test.

Why the MLS is promising but not ready for the office

The score was developed after the DIVAS trial had finished, using 45 selected markers from 111 candidates. That selection process can overfit a score to the dataset that produced it, even when later cohort findings are encouraging. The lipidomics analysis also included 113 of 195 randomized participants, so the analyzed subset may not perfectly represent everyone randomized.

External studies used an rMLS based on 42 lower-resolution variables reflecting 15 class-specific fatty-acid concentrations rather than the original 45-lipid score. Different measurement platforms can change how well a score transfers. PREDIMED also had randomization irregularities at some centers that led to retraction and republication of the main trial; its subgroup analyses deserve added caution. Finally, no standardized, reimbursed clinical workflow currently offers MLS-depth lipidomic testing. The score has a compelling research record and no established deployment path.

Glucose prediction works as a measurement tool, not yet as a superior diet plan

People can have very different glucose responses to the same meal. That observation led researchers at Weizmann and elsewhere to build algorithms that use personal data to predict postprandial glucose response, or PPGR, and steer people toward foods predicted to produce smaller excursions.

Smaller randomized trials supplied reasons to take the idea seriously. Ben-Yacov et al. reported better glycemic-control outcomes with a personalized postprandial-response-targeting diet than with a Mediterranean diet in people with prediabetes. In a pilot trial of people with newly diagnosed type 2 diabetes, Rein et al. found glycemic improvements with PPGR-based dietary guidance.

Neither result settles whether the algorithm adds value beyond good dietary counseling. The trials studied different populations and used different comparators. Newly diagnosed diabetes is also a period when people may respond strongly to almost any sustained dietary attention, and pilot trials cannot reliably isolate a small algorithm-specific effect.

The larger test was less flattering. In the Personal Diet Study, 156 adults with prediabetes or moderately controlled type 2 diabetes were randomized to a standard low-fat diet (n=75) or a personalized PPGR-algorithm diet (n=81) and followed for six months. Both groups received behavioral counseling, smartphone-app support, and continuous glucose monitoring at baseline, three months, and six months.

Glycemic variability improved at nearly the same rate in both arms. Mean amplitude of glycemic excursions fell by 0.83 mg/dL per month in the standard group (95% CI, 0.21 to 1.46; P=0.009) and 0.79 mg/dL per month in the personalized group (95% CI, 0.19 to 1.39; P=0.010). The between-group comparison was null (P=0.92), and HbA1c trajectories were parallel. The algorithm did not outperform standard counseling in this trial.

The study may have been too small to detect narrowly defined responder subgroups, and six months may not be long enough for HbA1c curves to diverge. Because both groups received equivalent app support and counseling, it also cannot separate the motivational effect of intensive support from the food-ranking algorithm. Those caveats justify more research. They do not turn a null comparison into proof of benefit.

Continuous glucose monitoring can still be useful for people with prediabetes or diabetes who want timely feedback on meals and habits. A small 30-day randomized study of 30 adults with prediabetes compared visible versus blinded CGM data alongside individualized nutrition therapy; Basiri et al. tested whether real-time feedback could enhance that therapy. But a CGM trace is data, not a dietary verdict, and the Personal Diet Study found no added glycemic benefit from layering this particular PPGR algorithm onto counseling and CGM.

FADS1 explains a real metabolic difference, with no proven clinical payoff

FADS1 encodes delta-5 desaturase, an enzyme involved in converting dietary linoleic acid and alpha-linolenic acid into longer-chain highly unsaturated fatty acids. The rs174547 variant changes that metabolic machinery. A 2022 meta-analysis by Wang et al. found that the variant consistently associated with long-chain PUFA blood levels across studies.

That signal also appeared in dietary research. Jäger et al. studied nut consumption and plant-oil intake in EPIC-InterAct, which included 7,498 type 2 diabetes cases and a 10,087-person subcohort, and in 928 genotyped PREDIMED participants assigned to nuts or control diets. In PREDIMED, rs174547 genotype significantly modified plasma phospholipid fatty-acid responses to nut and plant-oil intake (interaction P=0.003). CC carriers showed lower conversion of linoleic acid to longer-chain fatty acids.

Yet the investigators did not find that genotype changed the association between these dietary exposures and type 2 diabetes incidence. This distinction matters. A genotype can alter a biomarker without identifying a diet that changes disease risk more effectively for that genotype.

The clinical interaction analysis also faced a basic numbers problem: CC carriers account for about 15% of European populations, limiting power to detect a modest gene-by-diet effect on diabetes incidence. A null result could therefore miss a small effect, but it also remains compatible with no clinically meaningful effect. Research on adipose inflammation offers biological detail—Vaittinen et al. found that FADS1 genotypes modified eicosanoid-related inflammatory responses to a linoleic-acid-enriched diet—but tissue inflammation and blood fatty acids are not diabetes outcomes.

What to do with this now

Use the parts of the evidence that already clear the clinical bar. Improving dietary fat quality by replacing some saturated fat with unsaturated fat remains sensible regardless of whether you ever obtain a lipidomics panel. If you have prediabetes or type 2 diabetes, CGM may help you notice patterns and support behavior change, especially alongside qualified clinical care.

Be more skeptical of commercial claims that a glucose algorithm or a single genetic variant can write a diet prescription that beats standard evidence-based counseling. The MLS is the most persuasive of these tools as a research measure because it links an experimentally induced dietary shift to replicated prospective risk associations. The PPGR algorithm has supportive early trials but failed its largest available randomized comparison. FADS1 testing can describe fatty-acid metabolism, but it cannot yet tell you which dietary fat strategy will reduce your diabetes risk.

Precision nutrition can measure individual biology with growing accuracy. It has not yet earned the right to charge extra for certainty.